Roche

1Q Revenues: 15.1 billion CHF (+2%)

Comments: Pharmaceutical sales were 12.3 billion CHF, up 3% in the quarter. Key growth drivers in the quarter were the cancer medicine Tecentriq, the haemophilia medicine Hemlibra, the multiple sclerosis medicine Ocrevus and the breast cancer medicine Perjeta, partially offset by competition from biosimilars. Avastin sales were 1.5 billion CHF, down 13%. MabThera/Rituxan sales were down 15% to 1.4 billion CHF. Herceptin sales were down 24% to 1.2 billion CHF. Ocrevus sales were up 38% to 1.1 billion CHF. Perjeta sales were up 22% to 1.0 billion CHF. Actemra/RoActemrasaes were up 30% to 666 million CHF. Tecentriq sales were up 99% to 644 million CHF. Hemlibra sales were up 146% to 521 million CHF. Xolair sales were 468 million CHF, up 3%. Kadcyla sales were up 55% to 428 million CHF. Diagnostics Division sales were 2.9 billion CHF, down 1%.